JLK gets FDA OK for prostate cancer diagnosis AI solution
It will boost expanding into the US market with its Medihub Prostate can MR images and prostate-specific antigen
By Jun 25, 2024 (Gmt+09:00)
Macquarie eyes its 1st Korean data center valued around $722 mn
S.Korea's LS Materials set to boost earnings ahead of IPO process
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
POSCO gears up for carbon-free steelmaking with hydrogen
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
South Korea’s JLK Inc., an AI-based diagnosis solution and platform maker, announced on Monday that it got approval from the US Food and Drug Administration (FDA) for its prostate cancer diagnostic solution Medihub Prostate.
The solution aids prostate cancer diagnosis by analyzing prostate magnetic resonance (MR) images and assessing prostate-specific antigen (PSA) levels.
Prostate cancer is the most common cancer among men in the US, with a latent prostate cancer occurrence risk of up to 40%.
"Based on the FDA approval of MEDIHUB Prostate, we plan to pursue entry into the US market more aggressively," JLK's CEO Kim Dong-min said.
"We intend to sequentially apply for FDA approval for three additional AI solutions between August and October."
Write to Jeong Min Nam at peux@hankyung.com
-
Bio & PharmaKorea's JLK targets AI-based stroke care market in US
Jan 10, 2024 (Gmt+09:00)
2 Min read